Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Krell RD, Aharony D, Bruckner CK, Giles RE, Snyder DW (1990) Am Rev Resp Dis 141:978–987
Bernstein PR (1994) Drugs of the Future 19:217–220
Bruckner CK, Fedyna JS, Robertson JI (1990) J Pharm Exp Ther 252:77–85
Smith LJ, Geller S, Ebright L (1990) Am Rev Resp Dis 141:988–992
Smith LJ, Glass M, Minkwitz MC (1995) Am J Resp Crit Care Med 151:A378
Dahlen B, Zetterstrom O, Bjorck T, Dahlen SE (1994) Eur Resp J 7:324–330
Dahlen SE, Dahlen B, Eliasson E (1991) Adv Prost Thromb Leuk Res 21:461–464
Taylor IK, O’Shaughnessy KM, Fuller RW, Dollery CT (1991) Lancet 337:690–694
Calhoun WJ, Lavins BJ, Glass M (1995) Am J Resp Crit Care Med 151:A42
Spector S, Miller CJ, Glass M (1995) Am J Resp Crit Care Med 151:A379
Townley R, Glass M, Minkwitz MC (1995) Am J Resp Crit Care Med 151:A380
Kemp JP, Glass M, Minkwitz MC (1995) J Allergy Clin Immunol 95:351 (abstract)
Bateman ED, Holgate ST, Binks SM (1995) Allergy 50:320 (Abstract P-0709)
Lockey RF, Lavins BJ, Snader L (1995) J Allergy Clin Immunol 95:350 (abstract)
Hivid Roche®, Zalcitabin (ddC) Monographie (1995)
Eur Pat Appl, zit. nach CA (1985) 103:178579
Horwitz JP, Chua J, Noel M, Donatti JT (1967) J Org Chem 32:817–818
Lin TS, Chen MS, McLaren C, Gao YS, Ghazzouli I, Pru-soff WH (1987) J Med Chem 30:440–444
Beach JW, Kim O, Jeong LS, Nampalli S, Islam Q, Ahn SK, Babu JR, Chu CK (1992) J Org Chem 57:3887–3894
Motawia MS, Pedersen EB (1990) Liebigs Ann Chem 599-602
Kaskar B, Marcovac A (1989) J Heterocyclic Chem 26:1531–1533
Manchand PS, Belica PS, Holman MJ, Huang TN, Maehr H, Tarn SYK, Yang RT (1992) J Org Chem 57:3473–3478
Huryn DM, Okabe M (1992) Chem Rev 92:1745–1768
Whittington R, Brogden RN (1992) Zalcitabine. A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS). Drugs 44:656–683
Roche (1994) Fachinformation HIVID Roche®.
Bartlett JA, Benoit SL, Johnson VA, Quinn JB, Sepulveda GE, Ehmann WC, Tsoukas C, Fallon MA, Self PL, Rubin M (1996) Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party. Ann Intern Med 125:161–172
Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, Jones M, Facey K, Whitacre C, McAuliffe VJ, Friedman HM, Merigan TC, Reichman RC, Hooper C, Corey L (1996) Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med 334:1011–1017
Delta Coordinating Committee (1996) Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 348:283–291
Fischl MA, Olson RM, Follansbee SE, Lalezari JP, Henry DH, Frame FT, Remick SC, Salgo MP, Lin AH, Nauss-Ka-rol C (1993) Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy. Ann Intern Med 118:762–769
Graham NM, Hoover DR, Park LP, Stein DS, Phair JP, Mellors JW, Detels R, Saah AJ (1996) Survival in HIV-infected patients who have received zidovudine: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Ann Intern Med 124:1031–1038
Saravolatz LD, Winslow DL, Collins G, Hodges JS, Pet-tinelli C, Stein DS, Markowitz N, Reves R, Loveless MO, Crane L, Thompson M, Abrams D (1996) Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. N Engl J Med 335:1099–1106
Skowron G, Bozzette SA, Lim L, Pettinelli CB, Schaumburg HH, Arezzo J, Fischl MA, Powderly WG, Gocke DJ, Richman DD (1993) Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex. Ann Intern Med 118:321–330
Drugs Fut (1988) 13(4):302-304
Fujimoto Y, Yamabe S (Nippon Chemiphar Co., Ltd.) DE 2,941,869
Drugs Tod (1994) 30(6):515-525
Tsurumi K, Kyuki K, Niwa M, Kokuba S et al. (1986) Arz-neim Forsch/Drug Res 36(11), Nr. 12:1796–1800
Yoshioka M, Yamamoto T, Okai K (1991) Iyakuhin Ken-kyu 22(5):836–844, zit. nach CA (1992) 116:67029
Oshima J, Horai Y, Ishizaki T (1987) J Chromatogr 414(2):381–388
Yamamoto M, Masaki M, Nohira H (1990) Chiralty 2:280–283
Johnston CI (1990) Biochemistry and pharmacology of the renin-angiostensin system. Drugs 39:21–31
Menard J, Boger RS, Moyse DM, Guyene TT, Glassman HN, Kleinert HD Dose dependent effects of the renin inhibitor zankiren HCL after a single oral doses in mildly sodium-depleted normotensive subjects. Circulation 91:330-338
Mar31, S. 102
Boger RS, Glassman HN, Thys R (1993) Absorption and blood pressure response to the new orally active renin inhibitor, A-72517, in hypertensive patients. Am J Hypertension 6:103A
Williams PD, Calligaro DO, Colbert WE, Helton DR, Shetler T, Turk JA, Jordan WH (1991) General pharmacology of a new potent 5-hydroxytryptamine antagonist. Arzneimittelforsch 41:189–195
Schwartz SM, Goldberg MG, Gidda JS, Cerimele BJ (1994) Effect of zatosetron on ipecac-induced emesis in dogs and healthy men. J Clin Pharmacol 34:250–254
Cohen ML, Bloomquist W, Gidda JS, Lacefield W (1990) LY277359 maleate: a potent and selective 5-HT3 recpetor antagonist without gastroprokinetic activity. J Pharmacol Exp Ther 254:350–355
Chappell AS, Bay JM, Botzum GD, Cohen ML (1994) Zatosetron, a 5-HT3 receptor antagonist in a multicenter trial or acute migraine. Neuropharmacology 33:509–513
Franz PM, Mattiuz EL, Hatcher BL, deSante KA, Breau AP, Occolowitz JL, Dorman DE, Schmid CR, Goldberg MJ, Rubin A (1993) Disposition of zatosetron, a serotonin (5-HT3) receptor antagonist, in humans. Drug Metab Dispos 21:249–254
Robertson DW, Lacefield WB, Blomquist W, Pfeifer W, Simon RL, Cohen ML (1992) J Med Chem 35:310–319
Drugs Fut (1994) 19:850-853
Drugs Fut (1989) 14(1):26-28
Hashimoto M, Oku T, Ito Y, Namiki T et al. (Fujisawa Pharm. Co., Ltd) AU 8663589, EP 218999, JP 87096476, US 4734419
Tanaka Y, Shimojyo H, Hata T, Hashimoto M et al. (1994) Xenobiotica 24(5):461–471
Kanamaru M (1993) J Clin Pharmacol 33(11):1122
Drugs Fut (1993) 18:616-618
Alvarez FJ, Slade RT (1992) Pharm Res 9:1465–1473, zit. nach CA (1993) 118:219607
Stewart AO, Brooks DW (1992) J Org Chem 57:5020–5023
Bell RL, Lanni C, Malo PE, Stewart AO, Brooks DW, Rubin P, Carter GWI (1993) Ann NY Acad Sci 696:205–215
Carter GW, Young PR, Albert DH, Bouska J, Dyer R, Bell RL, Summers JB, Brooks DW (1991) J Pharmacol Exp Ther 256:929–937
Israel E, Rubin P, Kemp JP (1993) Ann Intern Med 119:1059–1061
Malo PE, Bell RL, Shaughnessy TK, Bouska J, Summers JB, Brooks DW, Carter GW (1993) Pulm Pharmacol 7:73–79
Abraham WM, Ahmed A, Cortes A, Sielczak M, Hinz W, Bouska J, Lanni C, Bell R (1992) Eur J Pharmacol 217:119–126
Zingarelli B, Squadrito F, Graziani P, Camerini R, Caputi AP (1993) Agents Actions 39:150–156
Laursen LS, Lauritsen K, Bukhave K (1994) Eur J Ga-stroenterol Hepatol 6:209 (abstract)
Hawkey C, Gassull M, Lauritsen K, Martin F, O’Morain C, Rask-Madsen J, Wright J, Dube L, Rountree L, Brout-man L (1994) Gastroenterology 106 (Suppl):A697 (abstract)
Israel E, Drazen J, Pearlman H, Cohn J, Rubin PA (1992) Allergy Clin Immunol 89:236–241
Wenzel S, Colin J, Trudeau J, Wilson W, Martin R, We-scott J (1994) Allergy Clin Immunol News (Suppl 2):Abstr. 302
Knapp HR (1990) New Engl J Med 323:1745–1748
Wong SL, Awni WM, Cavanaugh JH, el-Shourbagy T, Locke CS, Dube LM (1995) Clin Pharmacokinetics 29(Suppl 2):9–21
Awni WM, Braeckmann RA, Granneman GR, Wirr G, Dube LM (1995) Clin Pharmacokinetics 29(Suppl 2):22–33
Books DW, Bell RL, Carter GW, Dube LM, Rubin PD (1993) Drugs of the Future 18:616–618
Braeckman RA, Hui J, Cavanaugh JH, Rubin PD (1993) Clin Pharmacol Ther 53:P11–44 (abstract)
Granneman GR, Braeckman RA, Locke CS, Cavanaugh JH, Dube LM, Awni WM (1995) Clin Pharmacokinet 29 (Suppl 2):77–83
Awni WM, Braeckman RA, Cavanaugh JH, Locke CS, Linnen PJ, Granneman GR, Dube LM (1995) Clin Phar-macokinet 29 (Suppl 2): 112–124
bg Keller K, Greiner S, Stockebrand P (1992) Homöopathische Arzneimittel, Govi-Verlag: Bd. 3
Keller K, Greiner S, Stockebrand P (1992) Homöopathische Arzneimittel, Govi-Verlag: Bd. 3
Voisin H (1969) Materia medica des hom. Praktikers, Haug-Verlag Heidelberg: S. 1226
Keller K, Greiner S, Stockebrand P (1990) Horn. AM, Govi-Verlag: Bd. 3
DHU, Karlsruhe (1994) S: 310-311
Voisin H (1969) Materia rnedica des hom. Praktikers, Haug-Verlag: S. 1227
Boericke W (1994) Hom. Mittel und ihre Wirkungen, wis-senschaftl. Autorenverlag Leer/Ostfriesland: S.529-530
Drugs of the Future (1985) 10:281-285
Schneider MR, von Angerer E, Hohn W, Sinowatz F (1987) Antitumor activity of antiestrogenic phenylidoles on experimental prostate tumors. Eur J Cancer Clin Oncol 23(7):1005–1015
Robinson SP, Koch R, Jordan VC (1988) In vitro estroge-nic actions in rat and human cells of hydroxylated derivatives of D16726 (zindoxifene), an agent with known antimammary cancer activity in vivo. Cancer-Res 48(4):784–787
Stein RC, Dowsett M, Cunningham DC, Davenport J, Ford HT, Gazet JC, von Angerer E, Coombes RC (1990) Phase I/II study of the anti-oestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I/II Clinical Trials Committee study. Br J Cancer 61(3):451–453
Bulbena O, Esplugues JV, Escolar G, Gil L, Navarro C, Esplugues (1990) J Pharm Pharmacol 42:252–256
Escolar G, Navarro C, Sendros S, Bulbena O (1987) Arch Int Pharmacodyn Ther 290:128–137
Bulbena O, Esplugues JV, Escolar G, Navarro C, Esplugues J (1989) Prostaglandins Leukotrienes Essent Fatty Acids 36:119–123
Navarro C, Escolar G, Banos JE, Casanovas LI, Bulbena O (1988) Prostaglandins Leukotrienes Essent Fatty Acids 33:75–80
Jimenez E, Bosch F, Galmes JL, Banos JE (1992) Digestion 51:18–26
Mar 30, S. 1216
Maeda H (1988) Drugs Fut 13:841–842
Maeda H, Matsumoto T, Konno T, Iwai K, Ueda M (1984) J Prot Chem 3:181–193
Maeda H, Ueda M, Morinaga T, Matsumoto T (1985) J Med Chem 28:455–461
Oda T, Maeda H (1987) Cancer Res 47:3206–3211; zit. nach Lit. 1
Oda T, Sato F, Maeda H (1987) J Nat T Cancer Inst 79:1205–1211, zit. nach Lit. 1
Weber K, Osborn M (1969) J Biol Chem 244:4406
Tananka S, Numasaki Y, Maeda H (1991) Action mechanisms of zinostatin stimalamer (YM881). Gan to Kagaku Ryoho 18(13):2295–2300
Toge T, Jinushi K, Sawamura A, Matsuki K (1991) Study on the intra-tumor tissue concentration of zinostatin stimalamer in the liver following intra-arterial injection of zinostatin stimalamer (YM881) suspension. Gan to Kagaku Ryoho 18(10):1677–1680
Taguchi T, Saito T, Ota J, Nakao I, Ohashi K, Nakamura H, Konno T (1991) Phase II study of YM881 (zinostatin stimalamer) suspension injected into the hepatic artery. Research Group for Intra-arterial Injection therapy with YM881. Gan To Kagaku Ryoho 18(10):1665–1675
Saito T, Nakao I, Wakui A, Kurihara M, Niitani H, Konno T, Tsukagoshi S, Maeda H (1991) Phase I clinical study of zinostatin stimalamer (YM881) by intravenous injection. Gan To Kagaku Ryoho 18(8):1311–1318
Saito T, Nakao I, Wakui A, Niitani H, Kurihara M, Konno T, Tsukagoshi S, Maeda H (1991) Early phase II study of YM881 (zinostatin stimalamer) by intravenous injection, research group for intravenous YM881: Gan To Kagaku Ryoho 18(8):1319–1323
Krapcho J, Turk C, Cushman DW, Powell JR, DeForrest JM, Spitzmiller IR, Karanewsky DS, Duggan M, Rovnvak G, Schwartz J, Natarajan S, Godfrey JD, Ryono DE, Neubeck R, Atwal KS, Petrillo EW (1988) J Med Chem 31:1148–1160
US-Patent 4316906
Lacouriere Y, Provencher P (1989) Comparative effects of zofenopril and hydrochlorothiazide on office and ambulatory blood pressure in mild to moderate essential hypertension. Br J Clin Pharmacol 27:371–376
Salvetti A (1990) Newer ACE inhibitors. A look at the future. Drugs 40:800–828
Ambrosioni E, Borghi C, Magnani B (1995) The effect of the angiotensin-converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 332:80–85
Drugs Fut (1991) 12:787-780
Allen J, Tizot A (1986) J of Labelled Compounds and Ra-diopharmaceuticals XXIII:393–400
Allen J, Parent G, Tizot A (1986) J of Labelled Compounds and Radiopharmaceuticals XXIIL:807–813
Ahrens B, Schütz H, Seno H, Weiler G (1994) Arzneim Forsch 44:799–802
Guinebault P, Dubruc C, Hermann P, Thenot JP (1986) J Chromatogr 383:206–211
Hempel G, Blaschke G (1996) J Chromatogr B 675:131–137
Arbilla S, Allen J, Wick A, Langer SZ (1986) High affinity 3H-Zolpidem binding in the rat brain: an imidazopyridine with agonist properties at central benzodiazepine receptors. Eur J Pharmacol 130:257–263
Berlin I, Warot D, Hergueta T, Moliniert P, Bagot C, Puech AJ (1993) Comparison of the effects of zolpidem and tria-zolam on memory functions, psychomotor, and postural sway in healthy subjects. J Clin Psychopharmacol 13:100–106
Colle M, Rosenzweig P, Bianchetti G, Fuseau E, Ruffie A, Ruedas E, Morselli PL (1991) Nocturnal profile of growth hormone secretion during sleep induced by zolpidem: a double-blind study in young adults and children. Hormone Res 35:30–34
Debailleul G, Khalil FA, Lheureux P (1991) HPLC quantification of zolpidem and prothipendyl in a voluntary intoxication. J Anal Toxicol 15:35–37
Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF (1988) Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a pheno-thiazine neuroleptic. Psychopharmacol 96:163–166
Durand A, Thenot JP, Bianchetti G, Morselli PL (1992) Comparative pharmacokinetic profile of two imidazopyridine drugs: zolpidem and alpidem. Drug Metabol Rev 24:239–266
Fillastre JP, Geffroy-Josse S, Etienne I, Dhib M, Rosenzweig P, Danjou P, Dubruc C, Bianchetti G (1993) Phar-macokinetics and pharmacodynamics of zolpidem following repeated doses in hemodialyzed uraemic patients. Fundament Clin Pharmacol 7:1–9
Gamier R, Guerault E, Muzard D, Azoyan P, Chaumet-Riffaud AE, Efthymiou ML (1994) Acute zolpidem poisoning-analysis of 344 cases. J Toxicol Clin Toxicol 32:391–404
Hoehns JD, Perry PJ (1993) Zolpidem: a nonbenzodiaze-pine hypnotic for treatment of insomnia. Clin Pharm 12:814–728
Hulhoven R, Desager JP, Harvengt C, Hermann P, Guillet P, Thiercelin JF (1988) Lack of interaction between zolpidem and H2 antagonists, cimetidine and ranitidine. Int J Clin Pharmacol Res 8:471–476
Jonas JM, Coleman BS, Sheridan AQ, Kalinske RW (1992) Comparative clinical profiles of triazolam versus other shorter-acting hypnotics. J Clin Psychiat 53 Suppl: 19–34; discussion 32-33
Langtry HD, Benfield P (1990) Zolpidem. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 40:291–313
Mastain B, Vaiva G, Guerouau D, Pommery J, Thomas P (1995) Effet favorable du zolpidem sur un etat catatoni-que. Rev Neurol 151:52–56
Monti JM (1989) Effect of zolpidem on sleep in insomniac patients. Eur J Clin Pharmacol 36:461–466
Morselli PL (1993) Zolpidem side-effects (letter, comment). Lancet 342:868–869
Patat A, Trocherie S, Thebault JJ, Rosenzweig P, Dubruc C, Bianchetti G, Court La, Morselli PL (1994) EEG profile of intravenous zoplidem in healthy volunteers. Psychopharmacol 114:138–146
Pons G, Francoual C, Guillet P, Moran C, Hermann P, Bianchetti G, Thiercelin JF, Thenot JP, Olive G (1989) Zolpidem excretion in breast milk. Europ J Clin Pharmacol 37:245–248
Praplan-Pahund J, Forster A, Gamulin Z, Tassonyi E, Sauvanet JP (1990) Preoperative sedation before regional anaesthesia: comparison between zolpidem, midazolam and placebo. Brit J Anaesth 64:670–674
Wilkinson CJ (1995) The acute effects of zolpidem, administered alone and with alcohol, on cognitive and psycho-motor function. J Clin Psychiat 56:309–318
Beyer-Mears A, Mistry K, Diecke FP et al. (1996) Pharmacology 52:292–302
Inskeep PB, Ronfeld RA, Peterson MJ et al. (1994) J Clin Pharmacol 34:760–66
Ramasamy R, Oates PJ, Schaefer S (1997) Diabetes 46:292–300
Tesfamariam B, Palacino JJ, Weisbrod RM et al. (1993) J Cardiovasc Pharmacol 21:205–11
Drugs Fut (1995) 20(1):33-36
Mylari BL, Larson ER, Beyer TA, Zembrowski WJ et al. (1991) J Med Chem 34(1):108–122, zit. nach CA (1991) 114:42696
Mylari BL, Zembrowski WJ (1991) J Label Compound Radiopharm 29(2):143–148
Mylari BL, Zembrowski WJ (Pfizer, Inc.) EP 295051, zit. nach CA (1989) 111:134180
Mylari BL, Larson ER, Zembrowski WJ (Pfizer, Inc.) EP 222576 (JP 87114988, US 4939140), zit. nach CA (1987) 107:176055.
Inskeep BP, Ronfeld RA, Peterson MJ, Gerber N (1994) J Clin Pharmacol 34(7):760–766
Drugs Fut (1979) IV(10):758-759
(1996) Japan Pharmaceutical Reference, 4. Auflage, S. 273-276
Schotte A, Janssen PFM, Gommeren W, Luyten WHML, van Gompel P, Lesage AS, Loore K, Leysen JL (1996) Risperidone compared with new and reference antipsy-chotic drugs: in vitro and in vivo receptor binding Psych-pharmacology 124:57–73
Miiller-Spahn F, Dieterle D, Ackenheil M (1991) Clinical efficacy of zotepine in the treatment of schizophrenic negative symptoms. Fortschr Neurol Psychiat 51:30–35
Fleischhacker WW, Hummer M (1997) Drug treatment of schizophrenia in the 1990s. Drugs 53:915–929
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
von Bruchhausen, F. et al. (1999). Z. In: von Bruchhausen, F., et al. Hagers Handbuch der Pharmazeutischen Praxis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-58388-9_15
Download citation
DOI: https://doi.org/10.1007/978-3-642-58388-9_15
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-63569-4
Online ISBN: 978-3-642-58388-9
eBook Packages: Springer Book Archive